Dianthus Therapeutics, Inc..
DNTH.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of autoimmune diseases. The company's lead product candidate, DNTH103, is a potent, selective, and long-acting monoclonal antibody inhibitor of the classical complement pa...Show More
Better Health for All
-10
Dianthus Therapeutics is a clinical-stage biotechnology company entirely focused on developing next-generation therapies for severe autoimmune diseases such as generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN), and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
1
These diseases have unmet medical needs, with up to 80% of MMN patients not adequately managed by current standard of care.
2
The company reports no revenue from product sales and no products with negative health outcomes.
3
Phase 1 clinical trial data for DNTH103 in 60 healthy volunteers showed generally good tolerability with no serious adverse events or complement-related infections.
4
The company's R&D expenses were $16.1 million for the six months ended June 30, 2023, against total revenue of $1.4 million, indicating substantial investment in innovation.
5
The company mentions regulatory compliance with HIPAA and EU GDPR for data privacy.
6
Clinical trials are conducted in accordance with GCP and IRB approvals.
7
However, the company's risk disclosures include potential challenges in development, regulatory approval, manufacturing, and commercialization, and potential pricing challenges in foreign markets due to price controls and reimbursement limitations.
8
There is no specific information on programs to ensure equitable access for vulnerable populations or on patent flexibility.
Fair Money & Economic Opportunity
0
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune diseases.
1
The company's core business involves developing drugs like claseprubart (DNTH103) and DNTH212, not lending, insuring, moving, or storing money.
2
As such, it does not offer financial services or products to consumers. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's operations, aligning with the '0' tier definitions for each KPI.
Fair Pay & Worker Respect
20
Dianthus Therapeutics, Inc. provides 100% employer-funded health, dental, and vision insurance, including HSA contributions, FSA options, dependent care FSA, a 401K plan, life insurance, long/short-term disability insurance, and 12 weeks of parental leave.
1
No employees are represented by a union or covered by a collective bargaining agreement.
2
The company has reported an increased number of identity theft attempts using recruitment fraud, but no substantiated labor law or human rights violations have been documented.
3
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles regarding Dianthus Therapeutics, Inc.'s performance on any of the Fair Trade & Ethical Sourcing KPIs. The articles primarily cover corporate governance, financial matters, and internal codes of conduct, without detailing supplier-specific ethical sourcing policies, audits, certifications, or incident data.
Honest & Fair Business
-10
Dianthus Therapeutics' Code of Business Conduct and Ethics includes a whistleblower hotline and protection against retaliation for good faith reporting, but there is no evidence of independent investigation processes.
1
The company has not mentioned any financial restatements in the provided articles.
2
Deloitte & Touche LLP was appointed as the independent registered public accounting firm on September 11, 2023, and served as auditor since 2022.
3
The Code of Business Conduct and Ethics explicitly prohibits offering anything of value to government officials to influence decisions, aligning with anti-corruption principles.
4
Kind to Animals
0
No information regarding Dianthus Therapeutics, Inc. (DNTH.US) or its practices related to animal welfare, animal testing, animal-derived ingredients, or conservation efforts was found in the provided articles.
1
All articles pertain to Microsoft and do not contain data relevant to the 'Kind to Animals' ethical value for DNTH.US.
2
No War, No Weapons
0
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases.
1
Its revenue is derived from license agreements, not arms or defense contracts.
2
The company's research and development is focused on therapeutic applications, indicating no dual-use technology development.
3
There is no evidence of defense-related business activities, controversial weapons exposure, or investment in military technology.
4
The company's core business model does not involve any activities related to arms, defense, or conflict, and there is no indication of procurement from conflict zones or use of conflict minerals.
5
Therefore, several KPIs are marked as 'N/A' due to the nature of the business.
Planet-Friendly Business
0
The provided articles do not contain any specific, concrete data points or information regarding Dianthus Therapeutics, Inc.'s environmental performance, emissions, targets, resource use, waste management, or climate-related initiatives. Sustainability data for the company is explicitly stated as unavailable.
1
Respect for Cultures & Communities
0
The provided articles, primarily a Code of Business Conduct and Ethics, focus on internal corporate governance, ethical conduct for employees, and regulatory compliance.
1
They do not contain specific, quantifiable data or details regarding the company's engagement with local or indigenous communities, cultural preservation efforts, community-specific grievance mechanisms, or local economic contributions.
2
Therefore, no KPIs related to Respect for Cultures & Communities can be scored based on the available evidence.
Safe & Smart Tech
0
The provided articles do not contain any specific, concrete data points or facts related to Dianthus Therapeutics, Inc.'s performance on any of the 'Safe & Smart Tech' KPIs. explicitly states no specific data on DNTH.US or Safe & Smart Tech is provided.
1
, an SEC filing, also indicates data gaps for 'Safe & Smart Tech' metrics.
2
Articles and were throttled and yielded no data.
3
Therefore, all KPIs under this value must be omitted due to a lack of evidence.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Dianthus Therapeutics, Inc.'s performance on any of the Zero Waste & Sustainable Products KPIs. The articles primarily discuss financial highlights, clinical trial progress, personnel changes, investor events, and stock market correlation, with no information on waste management, product recyclability, packaging sustainability, or related initiatives.
1